AWM
BNGO icon

Apollon Wealth Management’s Bionano Genomics BNGO Stock Holding History

Apollon Wealth Management’s Portfolio BNGO Stock Details BNGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-26
Closed -$28K – 863
2022
Q3 		$28K Buy
+26
New +$34.3K ﹤0.01% 790

Other funds holding BNGO

AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Apollon Wealth Management's BNGO Position: Q4 2022 in Review

Apollon Wealth Management sold out of Bionano Genomics (BNGO) in Q4 2022, closing a stake of 26 shares — an estimated $28K sold.

Apollon Wealth Management first reported a position in BNGO in Q3 2022 and held it in 1 quarter. The position peaked at $28K in Q3 2022. 143 funds tracked by Wall St. Rank hold BNGO as of Q4 2022.

  • Apollon Wealth Management reported no remaining Bionano Genomics position as of Q4 2022 after selling out during the quarter.
  • Apollon Wealth Management sold 26 Bionano Genomics shares in Q4 2022, an estimated $28K.
  • Apollon Wealth Management first reported a position in Bionano Genomics in Q3 2022 and held it in 1 quarter.
  • Apollon Wealth Management's Bionano Genomics position peaked at $28K in Q3 2022.
  • 143 funds tracked by Wall St. Rank held Bionano Genomics as of Q4 2022.

Based on Apollon Wealth Management's 13F filing for Q4 2022, filed 15 Feb 2023.